Anderson Christopher D, Pinson C Wright, Berlin Jordan, Chari Ravi S
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-4753, USA.
Oncologist. 2004;9(1):43-57. doi: 10.1634/theoncologist.9-1-43.
Cholangiocarcinoma presents a formidable diagnostic and treatment challenge. The majority of patients present with unresectable disease and have a survival of less than 12 months following diagnosis. Progress has been made by the appropriate selection of patients for treatment options including resection, with the routine use of more aggressive resections in order to achieve margin-negative resections. This has resulted in longer survival times for these patients. Neoadjuvant and adjuvant therapies have, for the most part, not improved survival in patients with this tumor, and new strategies are needed to improve this line of therapy. The prognosis for unresectable patients is poor, and palliative measures should be aimed at increasing quality of life first and increasing survival second.
胆管癌在诊断和治疗方面面临着巨大挑战。大多数患者就诊时已处于不可切除阶段，诊断后生存期不足12个月。通过合理选择包括手术切除在内的治疗方案，常规采用更积极的切除术以实现切缘阴性切除，已取得了一定进展，这使得这些患者的生存期得以延长。新辅助和辅助治疗在很大程度上并未改善该肿瘤患者的生存率，因此需要新的策略来改进这一治疗方法。不可切除患者的预后较差，姑息治疗措施应首先着眼于提高生活质量，其次才是延长生存期。
